Bristol Myers announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has recommended approval of Breyanzi for the treatment of adult patients with diffuse large B-cell lymphoma, or DLBCL, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B, who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMY:
- Juno Therapeutics’ lisocabtagene maraleucel receives FDA orphan designation
- Bristol-Myers announces three-year follow-up results from CheckMate-816 study
- Zevra Therapeutics appoints Dixon to board of directors
- Bristol-Myers announces european approval of Sotyktu
- Evotec, Bristol-Myers expand strategic neurodegeneration partnership